Full-Time

Medical Review Senior Associate Scientist

Confirmed live in the last 24 hours

Amgen

Amgen

10,001+ employees

Develops biologic therapies for serious illnesses

No salary listed

Senior

Hyderabad, Telangana, India

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Requirements
  • MD/DO or international equivalent
  • 1 year of related drug safety experience
  • Knowledge of Amgen Medical review and Case Management SOPs and regulatory requirements for pharmacovigilance
  • Clinical knowledge of therapeutic area patient populations and drug class
  • Proficiency in technical safety systems including Safety Database and medical coding
  • Knowledge of safety data capture in Clinical Trials and Post Marketing setting
  • Knowledge of clinical trials and drug development
  • Knowledge of Amgen products and patient population (preferred)
Responsibilities
  • To support global individual case safety reports regulatory reporting compliance.
  • To assure medical validity of ICSRs and provide input to the activities of Medical Safety Review Team (MSRT)
  • Execute the medical review of ICSRs (narratives, coding, expectedness, causality and seriousness) to ensure quality reports.
  • To act as a point of contact for Case Management on medical content of ICSRs
  • Execute the medical review of ICSRs (narratives, coding, expectedness, causality and seriousness) to ensure quality reports. Produce medically accurate ICSRs reports
  • Execute ICSR case escalation as appropriate
  • Execute appropriate case follow up per SOPs
  • Support medical coding conventions, and systematic process improvements for ICSR medical review
  • Conduct reportability assessment for medical device associated events and /or product complaint associated events, and review for potential product problems.
  • Support Quality Assurance of ICSR medical review (if applicable)
  • Provide input on teams for interdepartmental and cross-functional initiatives including, process improvement, standards development, Standard Operating Procedures (SOP) creation, and metrics with regards to medical review (if applicable)
  • Perform other duties related to the position as necessary as defined in SOPs or as requested by their supervisor
  • Undertake activities delegated by the QPPV as detailed in the PV System Master File and maintain a state of inspection readiness
  • Be representative and point of contact for Health Authority Inspection and Internal Process Audits within the remit of role and responsibility
Desired Qualifications
  • MD/DO or international equivalent
  • 3 years of relevant work

Amgen develops medicines aimed at treating serious illnesses, focusing on biotechnology. The company researches, develops, and sells biologic therapies, which are medicines made from living organisms. These therapies target conditions like cancer, cardiovascular diseases, and autoimmune disorders. Amgen stands out from competitors by reinvesting a large portion of its earnings into research and development, ensuring a strong pipeline of new treatments. The goal of Amgen is to improve patient care and outcomes through the discovery of effective therapeutic solutions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Amgen's investment in AI aligns with trends in biotechnology innovation.
  • Institutional investments indicate strong market confidence in Amgen's growth.
  • FTC clearance of the Horizon merger may ease future regulatory hurdles.

What critics are saying

  • Competitors' AI-driven drug discovery could outpace Amgen's traditional R&D methods.
  • FTC scrutiny of mergers may complicate Amgen's future growth strategy.
  • Advancements in quantum technologies could pose a competitive threat to Amgen.

What makes Amgen unique

  • Amgen focuses on biologic therapies derived from living organisms.
  • The company has a strong pipeline of potential new therapies in development.
  • Amgen's acquisition of Horizon Therapeutics enhances its rare disease portfolio.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

MarketBeat
Jan 28th, 2024
Factory Mutual Insurance Co. Makes New Investment in Amgen Inc. (NASDAQ:AMGN)

Factory Mutual Insurance Co. purchased a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 53,500 shares of the medical research company's stock, valued at approxim

The Quantum Insider
Jan 16th, 2024
Honeywell Announces the Closing of $300 Million Equity Investment Round for Quantinuum at $5 Billion Pre-Money Valuation

JPMorgan Chase has one of the world's most highly regarded specialist teams working on quantum technologies within the financial services industry and has been working with Quantinuum and its predecessor companies since 2020.

ETF Daily News
Dec 17th, 2023
Northwest Quadrant Wealth Management LLC Invests $237,000 in Amgen Inc. (NASDAQ:AMGN)

Northwest Quadrant Wealth Management LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 883 shares of the medical research company’s stock, valued at approximately $237,000. A number of other institutional investors […]

Horizon Therapeutics
Sep 21st, 2023
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc | Horizon Therapeutics plc

The Investor Relations website contains information about Horizon Therapeutics plc's business for stockholders, potential investors, and financial analysts.

BioSpace
Sep 19th, 2023
Amgen-Horizon Merger Clearance a Setback to FTC’s Antitrust Enforcement Plans

The consent agreement struck between the FTC and Amgen and Horizon Therapeutics could have significant implications for ongoing and future M&A challenges, experts told BioSpace.